Adolescents with childhood-onset GHD: how do we get them to peak bone mass?
dc.contributor.author | Shalet, Stephen M | |
dc.date.accessioned | 2009-07-06T14:51:24Z | |
dc.date.available | 2009-07-06T14:51:24Z | |
dc.date.issued | 2006 | |
dc.identifier.citation | Adolescents with childhood-onset GHD: how do we get them to peak bone mass? 2006, 65 Suppl 2:17-22 Horm. Res. | en |
dc.identifier.issn | 0301-0163 | |
dc.identifier.pmid | 16707905 | |
dc.identifier.doi | 10.1159/000091750 | |
dc.identifier.uri | http://hdl.handle.net/10541/72615 | |
dc.description.abstract | The development of osteoporosis, with its attendant risk of fragility fracture, is in part related to the peak bone mass (PBM) achieved in early adulthood. Adolescence is a critical time for the acquisition of bone mass, with around 40% of skeletal mass being accrued during pubertal maturation. Growth hormone (GH) plays an integral role in the achievement of PBM after completion of linear growth, and several recent studies have suggested that GH replacement should continue in individuals with childhood-onset GHD until PBM has been attained - irrespective of the height achieved. In those with severe GHD after growth and pubertal development are complete, a seamless transition of GH therapy into adult life may be preferable to allowing a gap in GH treatment. The 'window of opportunity' concept for achieving PBM will, nevertheless, continue to be challenged by GHD teenagers who may resent the seamless continuation of GH replacement beyond adolescence. Preparation for this possibility should therefore begin during childhood, with all GHD teenagers being encouraged to remain on GH therapy until at least their mid-20s. | |
dc.language.iso | en | en |
dc.subject.mesh | Adolescent | |
dc.subject.mesh | Body Height | |
dc.subject.mesh | Bone Density | |
dc.subject.mesh | Human Growth Hormone | |
dc.subject.mesh | Humans | |
dc.title | Adolescents with childhood-onset GHD: how do we get them to peak bone mass? | en |
dc.type | Article | en |
dc.contributor.department | Christie Hospital NHS Trust, Manchester, UK. stephen.m.shalet@man.ac.uk | en |
dc.identifier.journal | Hormone Research | en |
html.description.abstract | The development of osteoporosis, with its attendant risk of fragility fracture, is in part related to the peak bone mass (PBM) achieved in early adulthood. Adolescence is a critical time for the acquisition of bone mass, with around 40% of skeletal mass being accrued during pubertal maturation. Growth hormone (GH) plays an integral role in the achievement of PBM after completion of linear growth, and several recent studies have suggested that GH replacement should continue in individuals with childhood-onset GHD until PBM has been attained - irrespective of the height achieved. In those with severe GHD after growth and pubertal development are complete, a seamless transition of GH therapy into adult life may be preferable to allowing a gap in GH treatment. The 'window of opportunity' concept for achieving PBM will, nevertheless, continue to be challenged by GHD teenagers who may resent the seamless continuation of GH replacement beyond adolescence. Preparation for this possibility should therefore begin during childhood, with all GHD teenagers being encouraged to remain on GH therapy until at least their mid-20s. |